Clinical Trials on Hepatic Malignancies

Total 4542 results

Case Comprehensive Cancer Center

Completed

Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging for Hepatic Malignancies

Hepatic Malignancies

United States
Xiao Chen

Recruiting

Role of FAPI PET/MR Combined With Gadoxetate Disodium in Assessing Hepatic Malignancies

Hepatic Malignancies

China
Incyte Corporation

Completed

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.

Advanced Malignancies

United States
H. Lundbeck A/S

Completed

Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects

Heptic Impairment

Germany
Amgen

Completed

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment

Hepatic Impairment | Solid Tumors | Hematologic Malignancies

United Kingdom, Netherlands, United States, France
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Peking University People's Hospital

Completed

To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients

Cirrhosis | Chronic Hepatics C Virus (HCV) Genotype 1 | Non-Cirrhotic | Treatment naïve

China
Amsterdam UMC, location VUmc

Completed

Optimization of Systemic Treatment Strategies in Elderly Patients With Advanced Solid Malignancies (OptiMal)

Colorectum Advanced Malignancies | Breast Advanced Malignancies | Prostate Advanced Malignancies

Netherlands
Novartis Pharmaceuticals

Completed

Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011

Normal Hepatic Function | Impaired Hepatic Function

United States
Novartis Pharmaceuticals

Completed

Effect of Hepatic Impairment on LDE225..

Normal Hepatic Function | Impaired Hepatic Function

Belgium, Germany, Israel, Bulgaria, United States
National University Hospital, Singapore

Recruiting

A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies

Metastatic Solid Malignancies | Advance Solid Malignancies

Singapore
Novartis Pharmaceuticals

Completed

Effect of Hepatic Impairment on LDK378 Pharmacokinetics

Normal Hepatic Function | Impaired Hepatic Function

United States
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Moderate Hepatic Impairment | Normal Hepatic Function

United States
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men

Severe Hepatic Impairment | Normal Hepatic Function

Bulgaria
Pfizer

Completed

Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction

Mild Hepatic Dysfunction | Moderate Hepatic Dysfunction

South Africa
Assistance Publique - Hôpitaux de Paris

Unknown

TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock (TRANSPORT)

Cancer | Septic Shock | Anemia

France
AHS Cancer Control Alberta
Cross Cancer Institute

Withdrawn

Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients

Metastatic Solid Malignancies | Locally Advanced Solid Malignancies

Canada
Kiromic, Inc.

Terminated

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

Cancer | Progressive Solid Malignancies | Refractory Solid Malignancies

United States
Hong Kong Children's Hospital

Recruiting

Ultrasound Measurements of Hepatic Vasculatures and Hepatic Doppler Assessment of Healthy Children

Portal Vein | Hepatic Veins | Hepatic Artery | Liver Circulation

Hong Kong
Curon Biopharmaceutical (Australia) Co Pty Ltd
Novotech (Australia) Pty Limited

Terminated

A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies

Relapsed Lymphoid Malignancies | Refractory Lymphoid Malignancies

Australia
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

Healthy Volunteers | Moderate Hepatic Impairment | Severe Hepatic Impairment

United States
Assistance Publique - Hôpitaux de Paris

Unknown

Patients' Outcome With Severe or Fulminant Hepatic Insufficiency, Hospitalized in the Public Hospitals of Paris (DEVINHEF)

Fulminating Hepatic Failure

France
Cristina Gasparetto
Agilent Technologies, Inc.

Active, not recruiting

Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT (NK-DCI)

Lymphoid Malignancies | Myeloid Malignancies

United States
Eisai Inc.

Completed

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

Hepatic Impairment | Hepatic Function

United States
Agios Pharmaceuticals, Inc.

Completed

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

Moderate Hepatic Impairment

United States
Vital Therapies, Inc.

Completed

Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure

Fulminant Hepatic Failure

United States
Vital Therapies, Inc.

Withdrawn

Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF) (ELAD)

Fulminant Hepatic Failure

United States
Ospedale Santa Croce-Carle Cuneo

Unknown

Intra-bone Cord Blood Transplantation in Patients With Haematological Malignancies

Advanced Haematological Malignancies | High Risk Haematological Malignancies

Italy
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Quality of Life in Patients Undergoing Total Pelvic Exenteration

Total Exenteration | Anterior or Posterior Pelvic Exenteration | Gynecologic Malignancies | Colorectal Malignancies | Urologic Malignancies

United States
Bausch Health Americas, Inc.

Terminated

Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

Severe Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

Hepatic Impairment | Normal Hepatic Function

United States
Cardiox Corporation

Terminated

Liver Function Assessment - Feasibility and Dosing Study

Hepatic Failure
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Part 1：r/r B-cell Malignancies | Part 2：B-cell Malignancies

United States, Poland, Israel, Ukraine
Merck Sharp & Dohme LLC

Completed

Belzutifan (MK-6482) Hepatic Impairment Study (MK-6482-020)

Moderate Hepatic Impairment

United States
EQRx International, Inc.

Completed

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

Severe Hepatic Impairment

United States
Pfizer

Completed

Evaluate Severe Hepatic Impairment on Dacomitinib PK

Severe Hepatic Impairment

United States
Takeda

Completed

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

Severe Hepatic Impairment

United States
Tel-Aviv Sourasky Medical Center
Meir Medical Center; Max Planck Institute for Infection Biology

Unknown

Neutrophil Extracellular Traps (NETs) Formation Following Chemotherapy and Their Role in Antitumor Activity

Pediatric Solid Malignancies | Pediatric Hematological Malignancies

Israel
Chinese University of Hong Kong

Completed

Minimally Invasive Evaluation of Dyspepsia by Combined Magnetically Controlled Capsule Endoscopy and Urea Breath Test: a Pilot Prospective Cohort Study (MCUDYSPEPSIA)

Dyspepsia | Gastroesophageal Reflux | Peptic Ulcer Disease | Pancreatobiliary Disease | Ugi Malignancies

Hong Kong
University Hospital, Strasbourg, France

Recruiting

Hydrodissection of the Hepatoduodenal Ligament (Duodenal)

Hepatic Lesions

France
Rennes University Hospital

Completed

Pharmacogenetic Study of Tacrolimus in Hepatic Transplant (CYPTAC'H)

Hepatic Transplantation

France
Maastricht University

Completed

Liver Glycogen Dynamics (LGD)

Hepatic Glycogen

Netherlands
Shire

Completed

Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants

Hepatic Impairment

United States
University of Michigan Rogel Cancer Center

Completed

Assessment Of Liver Function in Patients Undergoing Hepatic Irradiation (IC-Green)

Hepatic Irradiation

United States
Assiut University

Unknown

Implication of Fluid Strategies Upon Hepatic Outcome in Hepatobiliary Surgery

Hepatic Complication
Novartis Pharmaceuticals

Completed

Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment

Hepatic Failure

United States
Daiichi Sankyo, Inc.

Completed

A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment

Hepatic Impairment | Moderate Impaired Hepatic Function

United States
Mitsubishi Tanabe Pharma Corporation

Completed

PK Study in Subjects With Severe Hepatic Impairment (MCI-186-E05 HP)

Healthy | Severe Hepatic Impairment

Czechia, Hungary, Slovakia
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Malignancies

United States, Korea, Republic of, Australia, Ireland, United Kingdom
MEI Pharma, Inc.
Quotient Clinical

Completed

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143

Malignancies

United Kingdom
Pathway Therapeutics, Inc.

Completed

Study of PWT33597 Mesylate in Subjects With Advanced Malignancies

Malignancies

United States

Clinical Trials on Hepatic Malignancies

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations